Fludarabin monoterápiával kezelt krónikus lymphoid leukaemiás betegeink hosszú távú követése során szerzett megfigyeléseink.

Translated title of the contribution: Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia

F. Varga, D. Lehoczky, J. Demeter

Research output: Contribution to journalArticle

Abstract

Fludarabine has widely been studied in chronic lymphocytic leukemia (CLL), with impressive remission rates in refractory, relapsed or untreated disease. In our study the clinical response and survival of 9 patients with a mean follow-up time of 28 months after treatment with fludarabine as a single agent for CLL has been evaluated. Seven patients were previously treated. Partial remission was achieved in 8 patients. No complete remission was seen. The cytoreductive activity of fludarabine was excellent in all the 9 patients. The median time to progression was 13.5 months. The median survival time from entering the trial was 27.9 months. Our patients tolerated the fludarabine treatment extremely well. Although fludarabine has been established as the most active single agent in CLL, most patients will have recurrent disease. 7/9 patients relapsed in our study, and they were given further chemotherapy. Grade 4 hematologic toxicity was observed in 2 patients. During the fludarabine treatment the frequency of infections decreased, but in the following 12 months increased again. Three fludarabine-treated patients developed high-grade non-Hodgkin lymphoma. It is concluded that fludarabine is a highly useful agent in CLL.

Original languageHungarian
Pages (from-to)1731-1735
Number of pages5
JournalOrvosi Hetilap
Volume140
Issue number31
Publication statusPublished - Aug 1 1999

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Non-Hodgkin's Lymphoma
fludarabine
Survival
Therapeutics
Drug Therapy
Infection

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Fludarabin monoterápiával kezelt krónikus lymphoid leukaemiás betegeink hosszú távú követése során szerzett megfigyeléseink. / Varga, F.; Lehoczky, D.; Demeter, J.

In: Orvosi Hetilap, Vol. 140, No. 31, 01.08.1999, p. 1731-1735.

Research output: Contribution to journalArticle

@article{dd4a09dbd94f460692612aac6c2cbdef,
title = "Fludarabin monoter{\'a}pi{\'a}val kezelt kr{\'o}nikus lymphoid leukaemi{\'a}s betegeink hossz{\'u} t{\'a}v{\'u} k{\"o}vet{\'e}se sor{\'a}n szerzett megfigyel{\'e}seink.",
abstract = "Fludarabine has widely been studied in chronic lymphocytic leukemia (CLL), with impressive remission rates in refractory, relapsed or untreated disease. In our study the clinical response and survival of 9 patients with a mean follow-up time of 28 months after treatment with fludarabine as a single agent for CLL has been evaluated. Seven patients were previously treated. Partial remission was achieved in 8 patients. No complete remission was seen. The cytoreductive activity of fludarabine was excellent in all the 9 patients. The median time to progression was 13.5 months. The median survival time from entering the trial was 27.9 months. Our patients tolerated the fludarabine treatment extremely well. Although fludarabine has been established as the most active single agent in CLL, most patients will have recurrent disease. 7/9 patients relapsed in our study, and they were given further chemotherapy. Grade 4 hematologic toxicity was observed in 2 patients. During the fludarabine treatment the frequency of infections decreased, but in the following 12 months increased again. Three fludarabine-treated patients developed high-grade non-Hodgkin lymphoma. It is concluded that fludarabine is a highly useful agent in CLL.",
author = "F. Varga and D. Lehoczky and J. Demeter",
year = "1999",
month = "8",
day = "1",
language = "Hungarian",
volume = "140",
pages = "1731--1735",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "31",

}

TY - JOUR

T1 - Fludarabin monoterápiával kezelt krónikus lymphoid leukaemiás betegeink hosszú távú követése során szerzett megfigyeléseink.

AU - Varga, F.

AU - Lehoczky, D.

AU - Demeter, J.

PY - 1999/8/1

Y1 - 1999/8/1

N2 - Fludarabine has widely been studied in chronic lymphocytic leukemia (CLL), with impressive remission rates in refractory, relapsed or untreated disease. In our study the clinical response and survival of 9 patients with a mean follow-up time of 28 months after treatment with fludarabine as a single agent for CLL has been evaluated. Seven patients were previously treated. Partial remission was achieved in 8 patients. No complete remission was seen. The cytoreductive activity of fludarabine was excellent in all the 9 patients. The median time to progression was 13.5 months. The median survival time from entering the trial was 27.9 months. Our patients tolerated the fludarabine treatment extremely well. Although fludarabine has been established as the most active single agent in CLL, most patients will have recurrent disease. 7/9 patients relapsed in our study, and they were given further chemotherapy. Grade 4 hematologic toxicity was observed in 2 patients. During the fludarabine treatment the frequency of infections decreased, but in the following 12 months increased again. Three fludarabine-treated patients developed high-grade non-Hodgkin lymphoma. It is concluded that fludarabine is a highly useful agent in CLL.

AB - Fludarabine has widely been studied in chronic lymphocytic leukemia (CLL), with impressive remission rates in refractory, relapsed or untreated disease. In our study the clinical response and survival of 9 patients with a mean follow-up time of 28 months after treatment with fludarabine as a single agent for CLL has been evaluated. Seven patients were previously treated. Partial remission was achieved in 8 patients. No complete remission was seen. The cytoreductive activity of fludarabine was excellent in all the 9 patients. The median time to progression was 13.5 months. The median survival time from entering the trial was 27.9 months. Our patients tolerated the fludarabine treatment extremely well. Although fludarabine has been established as the most active single agent in CLL, most patients will have recurrent disease. 7/9 patients relapsed in our study, and they were given further chemotherapy. Grade 4 hematologic toxicity was observed in 2 patients. During the fludarabine treatment the frequency of infections decreased, but in the following 12 months increased again. Three fludarabine-treated patients developed high-grade non-Hodgkin lymphoma. It is concluded that fludarabine is a highly useful agent in CLL.

UR - http://www.scopus.com/inward/record.url?scp=0033176228&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033176228&partnerID=8YFLogxK

M3 - Article

VL - 140

SP - 1731

EP - 1735

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 31

ER -